Relay Therapeutics Ownership
| RLAY Stock | USD 7.50 0.36 4.58% |
Shares in Circulation | First Issued 2019-03-31 | Previous Quarter 130.8 M | Current Value 132.8 M | Avarage Shares Outstanding 80.1 M | Quarterly Volatility 50.1 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Relay |
Relay Stock Ownership Analysis
About 80.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.79. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Relay Therapeutics has Price/Earnings To Growth (PEG) ratio of 0.07. The entity recorded a loss per share of 2.52. The firm had not issued any dividends in recent years. Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Relay Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 320 people. To find out more about Relay Therapeutics contact MA MBA at 617 370 8837 or learn more at https://www.relaytx.com.Besides selling stocks to institutional investors, Relay Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Relay Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Relay Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Relay Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Relay Therapeutics Insider Trades History
Only 1.77% of Relay Therapeutics are currently held by insiders. Unlike Relay Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Relay Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Relay Therapeutics' insider trades
Relay Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Relay Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Relay Therapeutics backward and forwards among themselves. Relay Therapeutics' institutional investor refers to the entity that pools money to purchase Relay Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Logos Global Management Lp | 2024-06-30 | 2.6 M | Geode Capital Management, Llc | 2024-06-30 | 2.4 M | Boxer Capital Llc | 2024-06-30 | 1.8 M | Finepoint Capital Lp | 2024-06-30 | 1.6 M | Alphabet Inc | 2024-06-30 | 1.6 M | Dimensional Fund Advisors, Inc. | 2024-06-30 | 1.5 M | Goldman Sachs Group Inc | 2024-06-30 | 1.5 M | Mpm Oncology Impact Management Lp | 2024-06-30 | 1.3 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.2 M | Sb Investment Advisers (uk) Ltd | 2024-06-30 | 27.9 M | Vanguard Group Inc | 2024-06-30 | 11.7 M |
Relay Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Relay Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Relay Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Relay Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Relay Therapeutics Outstanding Bonds
Relay Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Relay Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Relay bonds can be classified according to their maturity, which is the date when Relay Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| RILIN 2875 12 JAN 32 Corp BondUS759470BB24 | View | |
| RILIN 3625 12 JAN 52 Corp BondUS759470BD89 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View |
Relay Therapeutics Corporate Filings
| 11th of September 2024 Other Reports | ViewVerify | |
8K | 9th of September 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 31st of July 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 23rd of April 2024 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Relay Stock Analysis
When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.